Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Elon...
and
Hello South America...
(don't leave them out)
kopfkissen - suppose your figures ‘were’ correct, at a MC £90m that’s a PE of 3. Don’t be silly, a PE of 3 for a rapid growth company. No, that’s just silly. A minimum PE of 12 probably a lot more given your figures don’t include any tests over and above the RTC allocation.
There is absolutely no way the RTC will only want 200k per week from ODX. They set a plan based on UK only demand based on the capabilities. At the time ODX could only make 100k per week but they committed 200k. They will find that firstly they will need more than they thought for the UK because it will required repeat testing, and secondly there will be huge interest from elsewhere. Omega are in a good bargaining position with Mologic, so they will have to work out commercially the best use of 2m tests per week. I am certain that even if Mologic tests never got to market, ODX could sell as many as they can make. I've said from the start the manufacturing capacity is where the value is, and the plan to go to 2m per week is huge. Looking at a facility in Dundee to add to Alva.
we may find that the IP owner is actually Abingdon Health, so we hold the licence to produce in the UK as part of UKRTC, Abingdon may choose to go with another or numerous partners globally and take royalty.
but superb news is we’re there... at the table for the UK
How is my maths wrong at £3 profile Snowking ? 200,000 x £3 = £600,000 per week x 50 weeks in a year (roughly) = £30,000,000 per year.
200,000 is just for the UK mate! You watch the globe scrable for this test now. Nothing comes close to it in terms of quality and scalability.
The next 6 months are going to be insane. ODX have the first mover advantage now over any home based antibody test of high quality.
Well done all who held on
Sorry my maths is wrong
I think your maths is wrong at £3
We will be selling 200,000 a week in 3 months time. How much profit per sale ? If £3 that is £30 million per year. Does that justify our current map ?
lets see what happeneds today